Innate Pharma SA (FR:IPH) has released an update.
Innate Pharma SA, a biotechnology company focused on cancer immunotherapies, is set to participate in several key investor conferences across New York, London, and Miami from November to December 2024. This participation highlights the company’s ongoing efforts to engage with investors and showcase its innovative therapeutic approaches. Innate Pharma is publicly traded on Euronext Paris and Nasdaq, making these conferences an important opportunity for potential stakeholders.
For further insights into FR:IPH stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
